US oil giant Exxon Mobil fourth quarter profits beat estimates, despite weaker oil prices and refining margins, driven by increased production in the Permian basin at home, and in Guyana.
Among the director dealings disclosed to markets in London today involved insiders at discount stationer The Works, and the AIM-traded Staffline Group.
Offshore wind developer Orsted said on Friday that Mads Nipper was stepping down from his position as president and chief executive, to be replaced by Rasmus Errboe, who is currently deputy CEO and chief commercial officer.
Fusion Antibodies announced on Friday that its OptiMAL validation project with the US National Cancer Institute (NCI) was progressing as planned.
Metals One announced on Friday that it has completed a preliminary economic assessment (PEA) for its Finland Black Schist Ni-Cu-Co-Zn Project, identifying the Rautavaara (R1) deposit as the key economic driver.
Texas-based energy giant Chevron reported fourth-quarter earnings of $3. 2bn on Friday, an increase from $2. 3bn a year earlier, although adjusted earnings of $3. 6bn fell short of analyst expectations.
Celadon Pharmaceuticals reported on Friday that it has received £0. 897m of a £1m drawdown request from its committed credit facility, with the remaining £0. 1m now expected in February.
Prospex Energy reported a significant increase in production and revenue from the Selva Malvezzi production concession in Italy on Friday, with gross revenue for the fourth quarter reaching €3. 38m, a 91% rise compared to the final three months of 2023.
Shares in Smiths Group surged on Friday after the engineering business said it was selling its electronic connectors unit and would demerge or offload the detection operation as part of a strategic review that includes extending its share buyback to £500m.
Pharma giant Novartis comfortably beat market forecasts with its fourth-quarter results on Friday, with the Swiss firm pointing to further growth in sales and profits in 2025.
Cohort announced the completed acquisition of EM Solutions on Friday, following earlier announcements in November and January.
Faron Pharmaceuticals announced on Friday that it has identified the final patient for its BEXMAB phase two dose optimisation study in refractory or relapsed myelodysplastic syndrome (r/r MDS) and its phase one and two study in frontline high-risk (HR) MDS.
Reabold Resources announced on Friday that it has completed the acquisition of additional shares in Rathlin Energy UK from Connaught Oil & Gas for £0. 7m, increasing its equity interest in Rathlin to about 79. 8%.
Gemfields reported total auction revenue of $196m for 2024 on Friday, as it continued to invest in the expansion of its Montepuez Ruby Mine (MRM) in Mozambique.
Focusrite said in an update on Friday that trading for the first half of its financial year was expected to align with the board’s expectations, with performance anticipated to be weighted towards the second half as channel destocking in the US eased.
International healthcare firm Alliance Pharma said on Friday that FY24 group profits would be in line with expectations despite a modest downturn in revenues.
Defence products manufacturer Avon Technologies said on Friday that Q1 trading was in line with expectations and that its outlook for the FY remained consistent with previous guidance.
James Halstead said it expects to hit market forecasts with its full-year forecasts, though increased confidence in international markets has been offset by subdued activity in its core UK market.
Tritax Big Box reported a strong 2024 operational performance in an update on Friday, having secured £22. 7m in additional contracted rent, including one of the UK’s largest pre-lets of the year - a one million square foot facility leased to a global e-commerce company.
Tribal Group's share price surged on Friday morning after the education tech and services group delivered a bullish fourth-quarter trading update and confident outlook for 2025.